BCL2 and neutropenia: Since BCL-2 inhibition exacerbates chemotherapy-induced neutropenia by suppressing granulopoiesis, while inhibition of BCL-XL can sensitize cancer cells to chemotherapy [44], DT2216 has the potential to be combined with chemotherapy for the treatment of different cancers.